



an Open Access Journal by MDPI

Neurodegeneration in Cognitive Impairment and Mood Disorders for Experimental, Clinical and Translational Neuropsychiatry

Guest Editors:

Dr. Simone Battaglia

1. Department of Psychology,
University of Turin, Turin, Italy
2. Center for Studies and
Research in Cognitive
Neuroscience, Department of
Psychology, University of
Bologna, Bologna, Italy

Dr. Masaru Tanaka

HUN-REN-SZTE Neuroscience
Research Group, Hungarian
Research Network, University of
Szeged (HUN-REN-SZTE), Szeged,
Hungary

Deadline for manuscript
submissions:

closed (31 October 2023)

Message from the Guest Editors

This Special Issue highlights the most recent advances in experimental, clinical, and translational research in the fields of neuropsychiatry, focusing on neurodegeneration and neural correlates in the development of cognitive impairment and psychiatric emotional disturbance. We cordially invite authors to contribute comprehensive review and original research articles focusing on (but not limited to) the following:

- Etiology, pathogenesis, and progression mechanisms;
- Early diagnosis including biomarkers, bioimaging, and biosensors;
- Prophylactic, disease-modifying, and therapeutic strategies, novel targets;
- Novel drug discovery and development, naturally driven biomedicines, natural bioactive molecules and vaccines;
- Preclinical in vitro models and animal models;
- Bench-to-bedside translational research;
- Bedside-to-bench translational research;
- Non-invasive brain stimulation (NIBS) to diagnosis and treatment of neurodegenerative and psychiatric disorders.



mdpi.com/si/121378



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)